Puma Biotechnology (PBYI) Shares Outstanding (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Shares Outstanding (Entity) came in at $50.9 million in Q1 2026, up 2.55% YoY from $49.6 million in Q1 2025, and up 0.93% on a QoQ basis from $50.4 million in Q4 2025.
Puma Biotechnology (PBYI) Shares Outstanding (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Shares Outstanding (Entity) data on file, last reported at $50.9 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 2.55% year-over-year to $50.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.9 million (up 2.55% YoY) and the FY2025 annual result came in at $50.4 million, up 2.65% from the prior year.
- Shares Outstanding (Entity) rose to $50.9 million in Q1 2026, from $50.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $50.9 million in Q1 2026 to a low of $44.9 million in Q1 2022.
- A 5-year average of $48.1 million and a median of $48.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) grew 12.56% — and 2026, when it climbed 2.55%.
- Tracing PBYI's Shares Outstanding (Entity) over 5 years: stood at $46.3 million in 2022, then climbed by 2.81% to $47.6 million in 2023, then gained by 3.06% to $49.1 million in 2024, then grew by 2.65% to $50.4 million in 2025, then rose by 0.93% to $50.9 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $50.9 million (Q1 2026), $50.4 million (Q4 2025), and $50.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 50.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.94 Mn |
| Mar 31, 2026 | 50.85 Mn |
| Dec 31, 2025 | 50.01 Mn |
| Sep 30, 2025 | 50.34 Mn |
| Jun 30, 2025 | 49.70 Mn |
| Mar 31, 2025 | 49.60 Mn |
| Dec 31, 2024 | 48.65 Mn |
| Sep 30, 2024 | 49.01 Mn |
| Jun 30, 2024 | 48.29 Mn |
| Mar 31, 2024 | 48.19 Mn |
| Dec 31, 2023 | 47.13 Mn |
| Sep 30, 2023 | 47.52 Mn |
| Jun 30, 2023 | 46.76 Mn |
| Mar 31, 2023 | 46.64 Mn |
| Dec 31, 2022 | 44.67 Mn |
| Sep 30, 2022 | 45.57 Mn |
| Jun 30, 2022 | 45.06 Mn |
| Mar 31, 2022 | 42.21 Mn |
| Dec 31, 2021 | 40.64 Mn |
| Sep 30, 2021 | 40.81 Mn |